In a 183-person retrospective cohort of Chinese adults with obesity but without diabetes, three months of once-weekly tirzepatide (5 mg) produced 2.87 kg greater body weight reduction (95% CI: −4.41 to −1.32 kg, p<0.001) compared to semaglutide (1.7 mg). Tirzepatide also delivered superior visceral fat reduction, better insulin resistance amelioration, and more than doubled the proportion of patients achieving ≥10% total weight loss (21.5 percentage points higher, p=0.003). Notably, appetite suppression and food craving control were statistically equivalent between the two drugs.
This finding is clinically meaningful but warrants careful contextual framing. Tirzepatide's dual GIP/GLP-1 receptor agonism has consistently outperformed semaglutide's single GLP-1 mechanism in landmark trials like SURMOUNT-1 vs. STEP-1, and this real-world dataset extends that signal to a non-diabetic East Asian population — a group underrepresented in Western pivotal trials and known to accumulate visceral adiposity at lower BMI thresholds. The comparable appetite suppression despite greater weight loss suggests tirzepatide's advantage may operate through enhanced metabolic efficiency or lipid partitioning rather than hunger control alone.
Limitations are significant: single-center, retrospective design; only 3-month follow-up; non-randomized allocation; and modest sample size preclude causal inference. The doses used — semaglutide 1.7 mg and tirzepatide 5 mg — are moderate, not maximal, which could understate semaglutide's ceiling effect. Overall, an incrementally confirmatory finding with important ethnic-specific relevance, pending larger prospective validation.